These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon? Lampertico P; Viganò M; Colombo M Liver Int; 2013 Feb; 33 Suppl 1():157-63. PubMed ID: 23286860 [TBL] [Abstract][Full Text] [Related]
3. Update on hepatitis B virus infection. You CR; Lee SW; Jang JW; Yoon SK World J Gastroenterol; 2014 Oct; 20(37):13293-305. PubMed ID: 25309066 [TBL] [Abstract][Full Text] [Related]
4. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735 [TBL] [Abstract][Full Text] [Related]
5. Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously. Cheng HR; Kao JH; Wu HL; Chen TC; Tseng TC; Liu CH; Su TH; Chen PJ; Chen DS; Liu CJ Liver Int; 2014 Jul; 34(6):e71-9. PubMed ID: 24119014 [TBL] [Abstract][Full Text] [Related]
6. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. European Association for the Study of the Liver J Hepatol; 2017 Aug; 67(2):370-398. PubMed ID: 28427875 [TBL] [Abstract][Full Text] [Related]
7. Treatment of chronic hepatitis B: Evolution over two decades. Yuen MF; Lai CL J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525 [TBL] [Abstract][Full Text] [Related]
8. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues? Papatheodoridis GV Liver Int; 2013 Feb; 33 Suppl 1():151-6. PubMed ID: 23286859 [TBL] [Abstract][Full Text] [Related]
9. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593 [TBL] [Abstract][Full Text] [Related]
10. The role of HBsAg quantification for monitoring natural history and treatment outcome. Martinot-Peignoux M; Lapalus M; Asselah T; Marcellin P Liver Int; 2013 Feb; 33 Suppl 1():125-32. PubMed ID: 23286856 [TBL] [Abstract][Full Text] [Related]
11. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. Liu CJ; Kao JH Semin Liver Dis; 2013 May; 33(2):97-102. PubMed ID: 23749665 [TBL] [Abstract][Full Text] [Related]
12. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues? Viganò M; Mangia G; Lampertico P Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088 [TBL] [Abstract][Full Text] [Related]
13. Prevention of hepatocellular carcinoma in hepatitis B virus infection. Lim SG; Mohammed R; Yuen MF; Kao JH J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903 [TBL] [Abstract][Full Text] [Related]
14. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241 [TBL] [Abstract][Full Text] [Related]
15. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518 [TBL] [Abstract][Full Text] [Related]
16. Latest developments in the treatment of hepatitis B. Dandri M; Petersen J Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309 [TBL] [Abstract][Full Text] [Related]
17. Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy. Chen J; Wang Z; Zhou B; Wang Y; Hou J Antivir Ther; 2012; 17(1):71-9. PubMed ID: 22267471 [TBL] [Abstract][Full Text] [Related]
18. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Wang LY; You SL; Iloeje UH; Chen CJ; Gastroenterology; 2010 Aug; 139(2):474-82. PubMed ID: 20434450 [TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224 [TBL] [Abstract][Full Text] [Related]
20. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ; Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]